Improving Accessibility to Patients with Interstitial Lung Disease (ILD): Barriers to Early Diagnosis and Timely Treatment in Latin America.

Delayed initiation of effective antifibrotic therapy in patients with interstitial lung diseases (ILD) may influence the progression and outcome of the disease. This study analyzes the differences in the journey of patients with ILD in the Brazilian and Mexican health systems. An evaluative study was conducted in reference centers for interstitial lung diseases in Brazil and Mexico with a panel of four specialists.

Latin American Registry of Idiopathic Pulmonary Fibrosis (REFIPI): Clinical Characteristics, Evolution and Treatment.

Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible and frequently fatal disease. Currently there are national and multinational registries in Europe, United States, Australia and China to better understand the magnitude of the problem and the characteristics of the IPF patients. However, there are no national or regional registries in Latin America, so the objective of this study was to carry out a Latin American registry that would allow the identification of IPF patients in our region.

[Community-acquired pneumonia: risk focus and family functionality].

Introduction: Community-acquired pneumonia is one of the five most prevalent causes of death worldwide; in Mexico, it accounts for more than 10% of the hospital admissions.

Objective: To identify the risk factors and the kind of family functionality associated to community-acquired pneumonia among adult patients.

Material And Methods: With the prior authorization of the research and bioethics committees, a study of cases and controls took place, where both groups were asked about the following variables: alcohol consumption or active smoking, conditions of house and family functionality, anti-flu and anti-pneumococcal vaccination, disablement, and chronic pulmonary disease, among others.